NasdaqCM - Nasdaq Real Time Price • USD
Aptevo Therapeutics Inc. (APVO)
As of 11:24 AM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 2 |
| Avg. Estimate | -12.84 | -6.53 | -20.17 | -8.07 |
| Low Estimate | -14.1 | -11.17 | -31.5 | -10.5 |
| High Estimate | -11.59 | -1.89 | -8.85 | -5.65 |
| Year Ago EPS | 17.16 | -54.12 | -62.48 | -20.17 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 2 | 2 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -52.14 | -49.28 | -33 | -18.04 |
| EPS Actual | 17.16 | -54.12 | -22 | -6.16 |
| Difference | 69.3 | -4.84 | 11 | 11.88 |
| Surprise % | 132.90% | -9.80% | 33.30% | 65.90% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -12.84 | -6.53 | -20.17 | -8.07 |
| 7 Days Ago | -11.59 | -11.17 | -31.5 | -10.5 |
| 30 Days Ago | -11.59 | -11.17 | -31.5 | -10.5 |
| 60 Days Ago | -0.36 | -0.32 | -1.33 | -1.28 |
| 90 Days Ago | -0.36 | -0.32 | -1.33 | -1.28 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | 1 | 1 |
| Up Last 30 Days | 1 | 1 | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | APVO | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -174.80% | -- | -- | 1.30% |
| Next Qtr. | 87.90% | -- | -- | 10.60% |
| Current Year | 67.70% | -- | -- | 5.10% |
| Next Year | 60.00% | -- | -- | 13.40% |
| Next 5 Years (per annum) | -- | -- | -- | 11.21% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Related Tickers
ALLR Allarity Therapeutics, Inc.
1.4496
+2.08%
REVB Revelation Biosciences, Inc.
2.1300
+3.90%
EFTR eFFECTOR Therapeutics, Inc.
1.8700
+5.06%
FNCH Finch Therapeutics Group, Inc.
2.4800
+9.25%
PBLA Panbela Therapeutics, Inc.
0.4300
-9.44%
WINT Windtree Therapeutics, Inc.
5.79
+6.23%
NBY NovaBay Pharmaceuticals, Inc.
0.0742
+2.34%
KA Kineta, Inc.
0.6370
+0.33%
RNAZ TransCode Therapeutics, Inc.
0.4599
+0.22%
FWBI First Wave BioPharma, Inc.
3.1900
+5.63%